CIK 0001829802
- Emerging growth company
Faeth Therapeutics, Inc.
Sign in to watch- Ticker
- FTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 512-200-2982
- Business address
- 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
- Former names
- Sensei Biotherapeutics, Inc.
- 4 Open-market buy 10% owner bought 8,000 shares at $13.75 ($110,000)
- 4 Open-market buy Director bought 8,000 shares at $13.75 ($110,000)
- 4 Open-market buy 10% owner bought 5,000 shares at an average $15.16 ($75,800)
- 4 Open-market buy Director bought 5,000 shares at an average $15.16 ($75,800)
- 4 Open-market buy Director bought 3,000 shares at $16.25 ($48,750)
- 4 Open-market buy 10% owner bought 3,000 shares at $16.25 ($48,750)
- 4 Open-market buy Director bought 5,000 shares at $16.25 ($81,250)
- 4 Open-market buy 10% owner bought 5,000 shares at $16.25 ($81,250)
- 4 Open-market buy Director bought 31,000 shares at an average $16.48 ($510,862)
- 4 Open-market buy 10% owner bought 31,000 shares at an average $16.48 ($510,862)
- 4 Open-market buy Director bought 20,300 shares at an average $17.79 ($361,070)
- 4 Open-market buy 10% owner bought 20,300 shares at an average $17.79 ($361,070)
- 4 Open-market buy 10% owner bought 9,802 shares at $18.88 ($185,062)
- 4 Open-market buy Director bought 9,802 shares at $18.88 ($185,062)
- 4 Open-market buy Director bought 11,786 shares at $19.77 ($233,009)
- 4 Open-market buy 10% owner bought 11,786 shares at $19.77 ($233,009)
- 4 Open-market buy Director bought 753 shares at $19.75 ($14,872)
- 4 Open-market buy 10% owner bought 753 shares at $19.75 ($14,872)
- 4 Conversion Director acquired 301,769 shares (conversion)
- 4 Conversion Director acquired 2,407,328 shares (conversion)
Page 11 of 13 · 245 filings